570 related articles for article (PubMed ID: 27230651)
1. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S55-63. PubMed ID: 27183526
[TBL] [Abstract][Full Text] [Related]
6. Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy.
Moke DJ; Schubert LE; Sun HY; Printz BF; Dietz AC
J Pediatr Hematol Oncol; 2018 Jul; 40(5):e283-e288. PubMed ID: 29432303
[TBL] [Abstract][Full Text] [Related]
7. Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
Ruiz-Pinto S; Pita G; Martín M; Alonso-Gordoa T; Barnes DR; Alonso MR; Herraez B; García-Miguel P; Alonso J; Pérez-Martínez A; Cartón AJ; Gutiérrez-Larraya F; García-Sáenz JA; Benítez J; Easton DF; Patiño-García A; González-Neira A
Breast Cancer Res Treat; 2018 Jan; 167(1):249-256. PubMed ID: 28913729
[TBL] [Abstract][Full Text] [Related]
8. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
10. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
11. Strain and left ventricular volumes for predicting cardiotoxicity: a life-saving approach in anthracycline cancer treatment?
Bergler-Klein J
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):968-9. PubMed ID: 26206463
[No Abstract] [Full Text] [Related]
12. Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
Robinson EL; Azodi M; Heymans S; Heggermont W
Curr Heart Fail Rep; 2020 Dec; 17(6):357-364. PubMed ID: 32964378
[TBL] [Abstract][Full Text] [Related]
13. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Magdy T; Burridge PW
Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
[TBL] [Abstract][Full Text] [Related]
14. Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity.
Ding Y; Du K; Niu YJ; Wang Y; Xu X
Oxid Med Cell Longev; 2022; 2022():5818612. PubMed ID: 35965684
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline cardiotoxicity: from bench to bedside.
Gianni L; Herman EH; Lipshultz SE; Minotti G; Sarvazyan N; Sawyer DB
J Clin Oncol; 2008 Aug; 26(22):3777-84. PubMed ID: 18669466
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
20. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
